首页> 外文期刊>Indian Journal of Psychological Medicine >Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
【24h】

Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?

机译:卢拉西酮诱导的血小板减少症:这是药物诱导的骨髓抑制的信号吗?

获取原文
           

摘要

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13–17 years of age. Lurasidone was previously indicated in the U.S. for the treatment of adults with schizophrenia and major depressive episodes with bipolar I disorder as monotherapy. We present a case of a 29-year-old male patient who was hospitalized with thrombocytopenia (WHO grade-3 toxicity) (unlabeled) along with extrapyramidal disorder, gastritis, and hyperprolactinemia within 2–3 months of initiation of tablet lurasidone 80 mg/day (Lurasid, Intas Pharmaceuticals) in bipolar depression. Dechallenge was found to be positive in three reactions except hyperprolactinemia (outcome unknown) during hospital stay. The terms anemia and leukopenia are well labeled/listed with the drug literatures of lurasidone. Thus, this case presents a strong probability of lurasidone to cause myelosuppression/bone marrow depression.
机译:美国食品药品监督管理局(FDA)已批准了一种非典型的抗精神病药Lurasidone(Latuda,Sunovion Pharmaceuticals)的补充新药应用,用于治疗13至17岁的青少年精神分裂症。卢拉西酮先前曾在美国被指定用于治疗患有精神分裂症和双相I型障碍的重度抑郁发作的成年人作为单一疗法。我们报道了一例29岁的男性患者,该患者在开始服用片剂80 mg / mg后2至3个月内因血小板减少症(WHO 3级毒性)以及锥体外系疾病,胃炎和高泌乳素血症而住院双相抑郁症的第二天(Lurasid,Intas Pharmaceuticals)。在住院期间,除高泌乳素血症(结果未知)外,其他三个反应中的去激惹反应均为阳性。卢拉西酮的药物文献中很好地标记/列出了术语贫血和白细胞减少症。因此,这种情况表示卢拉西酮极有可能引起骨髓抑制/骨髓抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号